Weekly Recap | Pfizer -0.22%, consensus target above spot
Weekly Review·- Pfizer closed the week at 27.66 USD, marking a minor decline of 0.22 % and slightly underperforming the S & P 500. - Key developments included regulatory approval for an updated COVID-19 vaccine in Canada and ongoing focus on the company's research pipeline and obesity program. - Covered by 28 institutions with a consensus buy rating and a target price of 28.875 USD, Pfizer continues to exhibit divergent market outlooks regarding its upside potential and dividend sustainability.